Skip to content
Screener

Immunome IMNM Other Non-Current Assets

Other Non-Current Assets at other companies

Arcus Biosciences logo
Arcus BiosciencesRCUS
$59M-14.5%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$8.23M+98.6%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$31K-44.6%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$11.24M+108%
Gilead Sciences logo
Gilead SciencesGILD
$295M-20.1%
Moderna logo
ModernaMRNA
$618M+2,709%

Other financials

Income statement

See full
Revenue--100%
Operating income-$59.3M-32.9%
Net income-$53.8M-29.3%
EPS (diluted)-$0.48+7.7%

Balance sheet

See full
Cash & equivalents$582.7M+126%
Total debt$3.7M-22.6%
Total equity$588.7M+91.7%
Total assets$619.8M+80.9%

Cash flow

See full
Operating cash flow-$58.6M-10.5%
CapEx$3.0M-18.1%
Free cash flow-$61.6M-8.7%

Valuation

See full
Market cap$2.92B+221%
Enterprise value$2.35B+204%
P/S728.3×+656×

Profitability

See full
Operating margin-5,947.9%-12,002pp
Net margin-5,593.8%-11,284pp
FCF margin-5,118.9%-8,601pp

Returns & leverage

See full
Return on equity-50.1%-10.8pp
Debt / equity0.0×
Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The source filing: Immunome’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:10 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219425
Line itemMarch 31, 2026December 31, 2025
Property and equipment, net17,08114,636
Operating right-of-use assets2,8282,978
Restricted cash210210
Other long-term assets5,3644,587
Total assets$619,792$683,188
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$5,534$3,339

Item 1. Financial Statements.

FAQ

What is Immunome's other non-current assets?
Immunome (IMNM) reported other non-current assets of $5.36M in Q1 2026.
How has Immunome's other non-current assets changed year-over-year?
Immunome's other non-current assets increased by 23.4% year-over-year, from $4.35M to $5.36M.
What is the long-term trend for Immunome's other non-current assets?
Over 2 years (2023 to 2025), Immunome's other non-current assets has grown at a 577.3% compound annual growth rate (CAGR), from $100K to $4.59M.
What does other non-current assets mean?
Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.

Ask your AI about Immunome's other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude